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Background
Colorectal cancer screening and treatment are rapidly evolving.
Aims
To reappraise stool-based colorectal cancer screening in light of changing test performance characteristics, lower test cost and increasing colorectal cancer care costs.
Methods
Using a Markov model, we compared faecal DNA testing every 3 years, annual faecal occult blood testing or immunochemical testing, and colonoscopy every 10 years.
Results
In the base case, faecal occult blood testing and faecal immunochemical testing gained life-years ⁄ person and cost less than no screening. Faecal DNA testing version 1.1 at $300 (the current PreGen Plus test) gained 5323 life-years ⁄ 100 000 persons at $16 900 ⁄ life-year gained and faecal DNA testing version 2 (enhanced test) gained 5795 life-years ⁄ 100 000 persons at $15 700 ⁄ life-year gained vs. no screening. In the base case and most sensitivity analyses, faecal occult blood testing and faecal immunochemical testing were preferred to faecal DNA testing. Faecal DNA testing version 2 cost $100 000 ⁄ life-year gained vs. faecal immunochemical testing when per-cycle adherence with faecal immunochemical testing was 22%. Faecal immunochemical testing with excellent adherence was superior to colonoscopy every 10 years.
Conclusions
As novel biological therapies increase colorectal cancer treatment costs, faecal occult blood testing and faecal immunochemical testing could become cost-saving. The cost-effectiveness of faecal DNA testing compared with no screening has improved, but faecal occult blood testing and faecal immunochemical testing are preferred to faecal DNA testing when patient adherence is high. Faecal immunochemical testing may be comparable to colonoscopy every 10 years in persons adhering to yearly testing.
INTRODUCTION
Colorectal cancer (CRC) affects up to 6% of the population and is the second leading cause of cancerrelated death in the US. 1 Each year, approximately 145 000 new cases are diagnosed and approximately 55 000 deaths are attributed to CRC in the US. 2 Screening decreases CRC incidence and mortality and is cost-effective, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] but only a minority of the population has been screened. 14, 15 Patient preferences for invasive vs. non-invasive screening tests vary, [16] [17] [18] and the availability of some tests may be limited. 19 In 2004, we first explored the potential role of faecal DNA testing (F-DNA) in average-risk persons. 20 We concluded that it could not be considered a substitute for traditional screening methods, but that it could have an important impact if it attracted persons who are not currently screened for CRC. 20 A prospective trial of the original PreGen Plus faecal DNA test (EXACT Sciences Corporation, Marlboro, MA, USA and LabCorp, Burlington, NC, USA) subsequently found the test to be superior to faecal occult blood testing (FOBT) in detecting CRC and large adenomas, 21 but its performance was inferior to our original estimates and its projected effectiveness and cost-effectiveness declined. 22 Colorectal cancer screening is a rapidly evolving field and key variables that affect estimates of effectiveness and cost-effectiveness are changing, including test performance characteristics and cost, and costs of CRC care. Technical advances in DNA stabilization, 23 DNA extraction from stool, 24 and use of gene-specific methylation 25 have improved the faecal DNA test. 26 Test cost has decreased to approximately $300 after write-offs (B. Berger, personal communication; EXACT Sciences Corporation). At the same time, bevacizumab (an antibody targeting vascular endothelial growth factor, a known regulator of tumour cell angiogenesis) and cetuximab (an antibody targeting the epidermal growth factor receptor, a tyrosine kinase important in the regulation of growth and survival pathways in CRC cells) [27] [28] [29] have emerged as novel treatments that enhance the efficacy of chemotherapy for advanced CRC, 28, 30 but also markedly increase treatment costs. 31 Our aims were to reappraise non-invasive stoolbased screening for colorectal neoplasia in persons unwilling or unable to undergo invasive screening with sigmoidoscopy or colonoscopy in light of changing faecal DNA test performance characteristics, 21, 26 lower test cost and increasing costs of CRC care. We compared F-DNA, guaiac-based FOBT and faecal immunochemical testing (FIT). Because adherence to yearly guaiac-based FOBT is poor, 15, [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] we examined in detail the potential impact of imperfect adherence on the effectiveness and cost-effectiveness of screening strategies. We previously examined the cost-effectiveness of other modalities, including colonoscopy. 11, 20, 22, 45 Although we focus here on stool-based testing, we report results for screening colonoscopy for purposes of comparison.
MATERIALS AND METHODS
Literature review and data sources
The sources for most model inputs have been described previously. 11, 20, 22, 45 
Decision analytic model
Our decision analytic model and its calibration and validation have been described in detail. 11, 20, 22, 45, 47 The model is constructed in TreeAge (TreeAge Software, Inc., Williamston, MA, USA) and the Natural History model is calibrated to reproduce the natural history and age-specific incidence and prevalence of colorectal adenomas and CRC in the US without screening. 11, 20, 22, 45, 47 Screening strategies are then superimposed on the Natural History model. As described previously, the model's predictions for conventional strategies are consistent with available clinical data. 11, 20, 22, 45, 47 For the current analysis, the model was modified to allow variable adherence rates every time a screening test was offered. To validate this modification, we have modelled a cohort representing the one studied by Mandel et al. 32, 33 with FOBT offered and followed up as in that study. 22 Our model predicts a 21% reduction in CRC incidence over 18 years vs. 20% observed in the study, 33 and a 36% reduction in CRC mortality over 16 years vs. 33% observed in the study. 32 
Natural history
The principal health states in the model are ( Figure 1 52 Model inputs are shown in Table 1 .
Screening strategies and surveillance
We compared Natural History, F-DNA, annual guaiacbased FOBT and annual FIT. First, a screening interval for F-DNA was selected that could be considered costeffective compared to a shorter screening interval, as described below. Screening strategies were superimposed on the Natural History model. In the base case, in all strategies, screening and surveillance with perfect adherence were performed up to and including age 80. Variable adherence was a principal focus of sensitivity analyses. After age 80, colonoscopy was performed only to evaluate symptoms. With colonoscopy, polyps were removed and CRCs were biopsied, if detected. If F-DNA, FOBT or FIT were positive, colonoscopy followed with polypectomy and biopsy as necessary. If colonoscopy was normal after a positive non-invasive test, the non-invasive test was assumed to be false positive and screening resumed in 10 years with the primary screening strategy. CRC was managed, and symptomatic CRC could be detected, as in the Natural History model.
In all strategies, after adenoma detection, patients underwent surveillance colonoscopy every 5 years. 53, 54 Persons developing CRC underwent colonoscopy at diagnosis, 3 years later and then every 5 years thereafter. 53, 54 Faecal occult blood testing and faecal immunochemical testing
In the FOBT strategy, annual testing 3, 53, 55 was offered with test performance characteristics as modelled previously (Table 1) . 22 FIT was evaluated with annual testing and test performance characteristics based on available literature [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] and FDA submission data from Enterix Inc., maker of InSure FIT. 67 Reported FIT sensitivities range from 30% to 100% for CRC and from 20% to 71% for large adenoma, with specificities of 86-99%. [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] In the base case for FIT, we assumed sensitivity of 76% for CRC, 40% for large adenoma and specificity of 91%. Derived from epidemiological and autopsy data. à The annual mortality rate applies to those surviving to the beginning of each year, reflecting exponential decay as the fraction of persons surviving decreases at a rate proportional to its value. § Sensitivity for small polyp set at (1 ) specificity). 
Faecal DNA testing
Faecal DNA testing version 1 was defined as the strategy using the prototype test evaluated by Imperiale et al. 21 This test had sensitivities of 52% for CRC and 18% for large adenoma and specificity of 94%. 21 F-DNA version 2 was defined as the strategy using the test recently reported by Itzkowitz et al. 26 This test represents the optimal marker combination of vimentin methylation and a DNA integrity assay, with sensitivity of 88% for CRC and specificity of 82%. 26 The sensitivity of F-DNA version 2 for large adenoma has not been reported formally. We assumed that the sensitivity for large adenoma of F-DNA version 2 was 18%, the same as for version 1. For F-DNA versions 1 and 2, we assumed that F-DNA could not distinguish normal from small adenoma. Thus, F-DNA was positive when the most advanced lesion was a small adenoma at a rate defined as (100% ) specificity).
The test currently available on the market is version 1.1 (PreGen Plus, LabCorp). Compared with version 1, version 1.1 includes a DNA stabilization buffer and an improved gel capture method for isolating DNA. 18, [23] [24] [25] When the version 1 test was enhanced in these ways in the recent study by Itzkowitz et al., sensitivity for CRC was 73% and specificity was 89%. 26 We assumed that the sensitivity for large adenoma of F-DNA version 1.1 was 18%, the same as for the other versions of the test. Before evaluating F-DNA strategies, an appropriate screening interval was selected. As described previously, 20 we examined F-DNA at progressively shorter screening intervals ranging from 1 to 5 years. Screening at a given interval (e.g. 4 years) was compared to screening at a longer interval (e.g. 5 years), yielding the incremental cost per life-year gained when shortening the interval. For the base case, we selected a screening interval consistent with the commonly accepted 'willingness to pay' threshold of $50 000 ⁄ life-year gained. [68] [69] [70] Thus, in the base case, F-DNA was offered every 3 years (see Results).
Screening colonoscopy
The screening colonoscopy strategy included colonoscopy every 10 years (COLO), if no adenomas were detected. Polyps were removed upon detection and masses underwent biopsy. Test performance characteristics and costs are presented in Table 1 . After detection of adenomas, surveillance was performed as described for all strategies above.
Cost inputs
Procedure cost estimates ranged from those derived from Medicare fee schedules (including professional fees and procedure reimbursement) to those reported from a health maintenance organization. Stage-specific costs of care for CRC were taken from published reports and available data on the costs of newer therapies for advanced CRC. 5, 9, 11, 20, 31, 47, [73] [74] [75] Our Natural History model is calibrated to SEER data on CRC stage distribution of 39% localized, 39% regional and 22% disseminated CRC. 22 After comparisons with data on CRC TNM stage distribution, we assumed that disseminated CRC in our model represented TNM Stage IV disease and that 2 ⁄ 3 of patients with regional CRC in our model had TNM Stage III disease. 76, 77 To account for the increasing costs of CRC care for advanced disease, we assumed that patients with TNM Stage III disease received three 8-week cycles of FOLFOX (oxaliplatin, infusional fluorouracil and leucovorin) chemotherapy, 78 resulting in an increased cost of $34 800 over the costs assumed in our previous analyses. 31 We assumed that patients with TNM Stage IV disease received four to six cycles of treatment including the emerging biological agents, bevacizumab and cetuximab, 28, 30, 48-51, 78, 79 resulting in an increased cost to $200 000. 31 Base case cost inputs incorporate these assumptions (Table 1) .
Costs were updated to 2006 dollars as necessary, using the medical services component of the consumer price index. 80 For each base case cost input, we used the average of the published values. Indirect costs were not included. We used a third-party payer perspective.
Clinical and economic outcomes
For each strategy, we determined CRC cases by stage in a cohort of 100 000 persons, deaths by cause and average life-years and costs per person (both discounted at 3% annually). 81 Cost-effectiveness of screening strategies
If one strategy afforded more life-years than another at higher expense, an incremental cost-effectiveness ratio was calculated. One-way sensitivity analyses were performed on all model inputs, including test performance characteristics and costs. Two-way sensitivity analyses were performed on variables determined to be influential on one-way sensitivity analyses. Threshold analyses were performed to identify critical values for variables at which specific conditions of interest were met (e.g. clinical equivalence, or cost-effectiveness at a willingness to pay of $50 000-100 000 ⁄ life-year gained 39 Thus, imperfect adherence was explored in detail in sensitivity analyses.
In the base case, we assumed perfect adherence for all strategies. This reflects the optimal possible 'efficacy' of the strategies. The results are useful because they reflect a strategy's impact in persons who adhere to it. Because imperfect adherence limits true 'efficacy' in larger cohorts, we performed extensive sensitivity analyses on adherence to estimate real-world 'effectiveness' with imperfect adherence.
RESULTS
Base case
Selection of screening interval for F-DNA. Faecal DNA testing version 1 every 3 years compared with every 4 years cost $39 200 ⁄ life-year gained, and every 2 years compared with every 3 years it cost $52 600 ⁄ life-year gained (Table 2) . Similarly, F-DNA version 2 every 3 years compared with every 4 years cost $47 700 ⁄ life-year gained, and every 2 years compared with every 3 years it cost $57 100 ⁄ life-year gained. Therefore, we selected a screening interval of 3 years for F-DNA.
Clinical outcomes with perfect adherence. Compared with no screening, all strategies reduced CRC incidence and mortality (Table 3) . FIT yielded the greatest number of discounted life-years ⁄ person, followed by COLO, F-DNA version 2, FOBT, F-DNA version 1.1 and F-DNA version 1. Without screening, a cohort of 100 000 persons experienced 5927 CRC cases, and CRC accounted for 2.4% of deaths. Compared with no screening, F-DNA version 1 decreased CRC incidence by 33% and CRC-related mortality by 49%, F-DNA version 1.1 decreased CRC incidence by 37% and CRCrelated mortality by 57%, FOBT decreased CRC incidence by 49% and CRC-related mortality by 66%, F-DNA version 2 decreased CRC incidence by 43% and CRC-related mortality by 63%, COLO decreased CRC incidence by 73% and CRC-related mortality by 80% and FIT decreased CRC incidence by 66% and CRCrelated mortality by 78%.
Cost-effectiveness with perfect adherence. Compared with no screening, all screening strategies increased life-expectancy at reasonable costs (Table 3) . FOBT and FIT yielded more average life-years per person than no screening, and achieved this at a lower cost -i.e. they were dominant compared with no screening. Compared with no screening, F-DNA version 1 gained 4466 life-years ⁄ 100 000 persons at an incremental cost of $21 200 ⁄ life-year gained, F-DNA version 1.1 gained 5323 life-years ⁄ 100 000 persons at an incremental cost of $16 900 ⁄ life-year gained and F-DNA version 2 gained 5795 lifeyears ⁄ 100 000 persons at an incremental cost of $15 700 ⁄ life-year gained. COLO gained 6185 lifeyears ⁄ 100 000 persons at an incremental cost of $9200 ⁄ life-year gained.
Faecal occult blood testing and FIT were preferred over all F-DNA versions. F-DNA versions 1 and 1.1 were dominated by FOBT and FIT. F-DNA version 2 was slightly more effective than FOBT, but at a very high incremental cost of $669 000 ⁄ life-year gained. FIT was dominant over all other strategies, including F-DNA version 2 (Table 3) . COLO was dominated by FIT and it cost $144 000 ⁄ life-year gained compared to FOBT. 
One-way and two-way sensitivity analyses
Changes in most variables did not significantly affect the comparisons between the F-DNA strategies and FOBT or FIT (Table 4) . If we assumed significantly worse test performance characteristics for FOBT than in the base case, the F-DNA strategies compared more favourably but still cost >$50 000 ⁄ life-year gained compared with FOBT. When we examined the low end of reported values for FIT test performance, it was still dominant over the F-DNA strategies. If FIT test cost increased to $95, the strategy was no longer cost-saving compared with no screening (it cost $8300 ⁄ lifeyear gained) and it cost $135 000 ⁄ life-year gained compared with FOBT, but it was still dominant over the F-DNA strategies. Changes in colonoscopy test performance, complication rate and costs did not affect the results significantly.
As the sensitivity for large adenoma of the F-DNA version 2 test improved, this strategy became progressively more effective than FOBT (Figure 2a) . With a sensitivity for large adenoma of 80%, F-DNA version 2 cost $87 500 ⁄ life-year gained compared with FOBT, but this incremental cost ⁄ life-year gained rose sharply as sensitivity for large adenoma decreased (Figure 2b) . At a test cost of $200, F-DNA version 2 cost <$50 000 ⁄ life-year gained compared with FOBT when F-DNA test sensitivity for large adenoma was >60% (Figure 2b) .
If we assumed lower CRC care costs because the novel, costly therapies were not used, no screening strategy was cost-saving anymore. Compared with no screening, FOBT cost $8000 ⁄ life-year gained, FIT cost $43 000 ⁄ life-year gained, F-DNA version 1 cost $33 100 ⁄ life-year gained, F-DNA version 1.1 cost $28 800 ⁄ life-year gained and F-DNA version 2 cost $27 700 ⁄ life-year gained. However, the incremental costeffectiveness ratios comparing the F-DNA strategies to FOBT and FIT were not affected significantly (Table 4) .
Threshold analyses on F-DNA test cost
Faecal DNA testing test cost would need to be significantly lower than the $300 assumed in the base case to make any of the F-DNA strategies competitive with FOBT. F-DNA test cost would need to fall to $40 for FOBT to cost >$50 000 ⁄ life-year gained compared to F-DNA version 1.1. F-DNA test cost would need to fall to $60 for F-DNA version 2 to cost <$50 000 ⁄ life-year gained compared to FOBT.
Even when the F-DNA test was assumed to be free, FIT cost only $9200 ⁄ life-year gained compared to F-DNA version 1 and $8100 ⁄ life-year gained compared to F-DNA version 1.1, and it still dominated F-DNA version 2.
Monte Carlo simulation focusing on test performance characteristics
When test performance characteristics for all stoolbased tests were varied within the ranges reported in the literature (Table 1) Compared with F-DNA version 1.1, FOBT was dominant in 88% of iterations, it cost between $100 000 and $1 000 000 ⁄ life-year gained in 18% of iterations, and it was more costly in the remainder. Compared with FOBT, F-DNA version 2 was dominant in 64% of iterations, it cost <$100 000 ⁄ life-year gained in 1% of iterations, it cost between $100 000 and $1 000 000 ⁄ life-year gained in 28% of iterations, and it was more costly in the remainder. Compared with F-DNA version 2, FIT was dominant in 100% of iterations.
Sensitivity analyses on adherence with testing
As the per-cycle (per-year) adherence with testing decreased with FOBT and FIT, the effectiveness of FOBT decreased steadily, and the effectiveness of FIT began to decrease significantly when the per-cycle adherence fell below approximately 60% (Figure 3) .
Faecal DNA testing version 1.1 (with 100% adherence) became more effective than FOBT when the per-cycle adherence with FOBT fell below 85%. F-DNA version 1.1 cost $100 000 ⁄ life-year gained compared with FOBT when per-cycle adherence with FOBT was 49%, and $50 000 ⁄ life-year gained when the per-cycle adherence with FOBT was 31% (Figure 4) .
Faecal DNA testing version 2 (with 100% adherence) became more effective than FIT when the per-cycle adherence with FIT fell below 50%. F-DNA version 2 cost $100 000 ⁄ life-year gained compared with FIT when per-cycle adherence with FIT was 22%, and $50 000 ⁄ life-year gained when the per-cycle adherence with FIT was 13% ( Figure 5 ). Imperfect adherence with F-DNA affected the comparisons with FOBT and FIT. To illustrate, when the per-cycle adherence with F-DNA version 1.1 was 50%, F-DNA version 1.1 became more effective than FOBT when the per-cycle adherence with FOBT fell below 35% and it cost $100 000 ⁄ life-year gained compared with FOBT when per-cycle adherence with FOBT was 26%. Similarly, when the per-cycle adherence with F-DNA version 2 was 50%, F-DNA version 2 became more effective than FIT when the per-cycle adherence with FIT fell below 19% and it cost $100 000 ⁄ life-year gained compared with FIT when per-cycle adherence with FIT was 12%.
DISCUSSION
Colorectal cancer screening and treatment are rapidly evolving fields, necessitating reappraisal of the effectiveness and cost-effectiveness of screening strategies as key variables change. Our current analyses focused on the latest test performance characteristics and costs of non-invasive, stool-based tests, and the increasing costs of care for advanced CRC. Our results lead to four major conclusions. First, if CRC treatment costs increase significantly because of the use of novel biological therapies, FOBT and FIT could improve clinical outcomes while also achieving cost savings. Secondly, recent improvements in test performance and lower test cost have translated into enhanced cost-effectiveness for F-DNA compared with no screening, but FOBT and FIT are likely to be preferred to F-DNA when patient adherence with yearly testing is high. Thirdly, adherence over time is a key determinant of the effectiveness of strategies that rely on frequent testing, and F-DNA with screening every 3 years could be costeffective compared with FOBT and FIT in populations with poor adherence to yearly testing. Fourthly, in persons who can adhere to yearly testing, highly sensitive and relatively inexpensive stool-based testing such as FIT may be comparable to screening COLO.
Before the current era of novel but costly treatments for advanced CRC, multiple analyses concluded that CRC screening is cost-effective. 3-13, 20, 22 Screening had been estimated to be cost-saving only when very low screening costs were assumed. 83 Our current analyses demonstrate how FOBT and FIT could not only decrease CRC incidence and mortality, but could actually decrease total overall CRC-related costs (screening, testing, complications and CRC care) if advanced CRC is treated with novel, costly therapies. 28, 30, 31, 48-51, 78, 79 It is rare for medical interventions to improve outcomes as well as decrease costs. Therefore, the question is often whether an intervention is 'cost-effective'. We have previously estimated that screening 75% of the US population with conventional methods could increase overall CRC-related costs by $1-3 billion ⁄ year, accounting for savings in CRC care. 22 However, if costly therapies for advanced CRC become widely used, the economic benefit of prevention and early detection may become large enough that overall savings could be realized by screening.
With current test cost of $300, F-DNA version 1.1 (the currently available test PreGen Plus, LabCorp) and F-DNA version 2 (the refined test as in Itzkowitz et al.
26
) were both cost-effective compared with no screening. Assuming the high advanced CRC care costs associated with novel biological therapies, these strategies cost approximately $17 000 ⁄ life-year gained (upper 95% confidence interval of approximately $22 000 ⁄ life-year gained). Without the use of novel therapies for advanced CRC, these strategies were still cost-effective compared with no screening (<$30 000 ⁄ life-year gained). However, FOBT and FIT were preferred to all F-DNA strategies when they were not compromised by poor adherence.
With current test performance characteristics and good adherence, substantial decreases in test cost would be required for any F-DNA test to become costeffective compared with FOBT. F-DNA test cost would need to be $40-60 for F-DNA versions 1.1 and 2 to compare favourably with FOBT at a threshold of $50 000 ⁄ life-year gained. More dramatically, FIT dominated F-DNA strategies in most sensitivity analyses, Figure 3 . Impact of adherence on the effectiveness of faecal occult blood testing (FOBT) and faecal immunochemical testing (FIT). As adherence with yearly testing decreased, the effectiveness of FOBT decreased steadily, and the effectiveness of FIT decreased significantly with per-cycle adherence below 60%. and it was preferred even when the F-DNA test was assumed to be free.
Early detection of CRC, as well as CRC prevention through removal of adenomas, underlies the benefit of screening. In the base case, we assumed low F-DNA sensitivity for large adenoma. Better sensitivity for large adenoma would improve F-DNA's effectiveness (Figure 2a ), but the effect appears less dramatic than we expected initially. This result depends on the assumption that most CRCs remain localized or regional for several years, and can therefore be detected at a high rate with a relatively sensitive test that is performed every 3 years. Similarly, for adenomas that 'dwell' for many years, repeated testing with only a fair test has a reasonably high cumulative sensitivity. The predictions of our model as regards the effectiveness of FOBTs are very close to the results of clinical trials, 22, 32, 33 giving us confidence as regards our predictions for F-DNA. However, if the fraction of rapidly advancing adenomas or tumours is higher than reflected in our current model, the benefit of improved sensitivity for large adenoma may be underestimated. Not surprisingly, we found that adherence over time is a key determinant of the effectiveness of strategies that rely on frequent testing (Figure 3) . Even in the idealized setting of a controlled trial, adherence to annual or biannual FOBT is less than ideal. 32, 33, 36, 38 In clinical practice, it has been difficult to achieve ongoing high rates of adherence with FOBT, 39, 42 and the follow-up of abnormal tests is difficult to ensure. 32, 33, 36, 38, 41, 61 Furthermore, patient preferences for screening options vary. 16, [84] [85] [86] [87] [88] [89] [90] Because changing the adherence rates of multiple strategies simultaneously is cumbersome, we compared F-DNA with perfect adherence against FOBT and FIT with imperfect adherence (Figures 4 and 5) . It is Figure 5 . Impact of adherence on the effectiveness and costeffectiveness of faecal DNA testing (F-DNA) version 2 compared with faecal immunochemical testing (FIT). F-DNA version 2 became more effective than FIT when the per-cycle adherence with FIT fell below 50%, and it cost an incremental $100 000 ⁄ lifeyear gained when per-cycle adherence with FIT was 22%.
conceivable that F-DNA could be considered costeffective compared with FOBT or FIT in populations that demonstrate good to excellent adherence with testing every 3 years, but which would otherwise have very poor adherence with yearly testing. Further study is required in this area.
In persons adhering perfectly with screening, which reflects optimal efficacy, screening COLO decreased CRC incidence more than annual FIT, but the average life-expectancy with FIT was higher than with screening colonoscopy. This is explained by the fact that most CRCs were diagnosed at treatable stages. The generalizable conclusion is that among persons who can comply with frequent testing, highly sensitive and inexpensive non-invasive testing may be comparable to much less frequent screening with colonoscopy.
The current reappraisal raises important points when compared with our first analysis of F-DNA. 20 As F-DNA's test performance has improved and its cost has decreased, it has become more cost-effective when compared with no screening, an effect that is accentuated as the cost of CRC care increases. However, colonoscopy remains preferred over F-DNA with current parameters. In our first analysis, we did not focus on the comparison between stool-based tests, which is the principal subject of our current reappraisal. Our current results highlight that, in the setting of good adherence, FOBT and FIT are likely to be preferred to F-DNA. Our analysis has some limitations. Indirect costs were not included. Patterns of adherence over time are likely to be complex, and such considerations are beyond the scope of the current analyses. Finally, as in all decision analyses, there is uncertainty surrounding important inputs. However, we have addressed the key variables in extensive sensitivity analyses to be able to draw conclusions that may focus future clinical research and inform policy decisions.
In conclusion, our analyses suggest that as the costs of care for advanced CRC increase because of use of novel but costly biological therapies, screening with reasonably effective and inexpensive methods such as FOBT and FIT can be not only cost-effective, but also potentially cost-saving. The evolution of test performance characteristics and decrease in test cost for F-DNA have translated into improved cost-effectiveness for F-DNA compared with no screening, but presently FOBT and FIT remain preferred to F-DNA in populations with high adherence to yearly testing. F-DNA with excellent adherence can be considered cost-effective compared with FOBT or FIT in populations with very poor adherence to yearly testing. With excellent annual adherence, sensitive and inexpensive stool-based testing such as FIT may be comparable to screening colonoscopy.
